ZYDUSLIFE.NS Profit & Loss
Zydus Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 7 years on file
(FY2019-20 to FY2025-26)
· fetched 2026-08-24 01:31
| Line item | FY2019-20 | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹142.53 Bn | ₹151.02 Bn | ₹152.65 Bn | ₹172.37 Bn | ₹195.47 Bn | ₹232.41 Bn | ₹271.48 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹142.53 Bn | ₹151.02 Bn | ₹152.65 Bn | ₹172.37 Bn | ₹195.47 Bn | ₹232.41 Bn | ₹271.48 Bn | SegmentRevenueFromOperations |
| Other Income | ₹1.14 Bn | ₹0.37 Bn | ₹2.25 Bn | ₹1.87 Bn | ₹2.84 Bn | ₹2.69 Bn | ₹5.09 Bn | OtherIncome |
| Total Income | ₹143.67 Bn | ₹151.39 Bn | ₹154.90 Bn | ₹174.24 Bn | ₹198.31 Bn | ₹235.11 Bn | ₹276.58 Bn | Income |
| Cost of Materials Consumed | ₹34.60 Bn | ₹38.88 Bn | ₹40.43 Bn | ₹41.23 Bn | ₹45.80 Bn | ₹43.73 Bn | ₹51.10 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹15.54 Bn | ₹14.71 Bn | ₹18.65 Bn | ₹19.49 Bn | ₹18.98 Bn | ₹21.50 Bn | ₹30.70 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-0.94 Bn | ₹-1.49 Bn | ₹-3.62 Bn | ₹2.38 Bn | ₹-2.50 Bn | ₹-1.85 Bn | ₹-8.88 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹24.14 Bn | ₹24.90 Bn | ₹24.34 Bn | ₹27.66 Bn | ₹31.38 Bn | ₹36.81 Bn | ₹44.18 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹3.42 Bn | ₹1.64 Bn | ₹1.27 Bn | ₹1.30 Bn | ₹0.81 Bn | ₹1.66 Bn | ₹4.39 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹6.96 Bn | ₹7.25 Bn | ₹7.13 Bn | ₹7.23 Bn | ₹7.64 Bn | ₹9.16 Bn | ₹14.08 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹41.35 Bn | ₹40.61 Bn | ₹39.45 Bn | ₹43.02 Bn | ₹47.97 Bn | ₹61.64 Bn | ₹69.63 Bn | OtherExpenses |
| Total Expenses | ₹125.08 Bn | ₹126.50 Bn | ₹127.64 Bn | ₹142.30 Bn | ₹150.08 Bn | ₹172.65 Bn | ₹205.20 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹18.59 Bn | ₹24.90 Bn | ₹27.25 Bn | ₹31.94 Bn | ₹48.23 Bn | ₹62.46 Bn | ₹71.38 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-3.64 Bn | ₹-2.05 Bn | ₹1.13 Bn | ₹-6.04 Bn | ₹-0.14 Bn | ₹-2.20 Bn | ₹-5.17 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹14.95 Bn | ₹22.85 Bn | ₹28.38 Bn | ₹25.90 Bn | ₹48.09 Bn | ₹60.27 Bn | ₹66.21 Bn | ProfitBeforeTax |
| Tax Expense | ₹3.20 Bn | ₹1.47 Bn | ₹5.12 Bn | ₹5.88 Bn | ₹9.78 Bn | ₹14.12 Bn | ₹15.95 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹12.04 Bn | ₹21.85 Bn | ₹46.18 Bn | ₹20.92 Bn | ₹39.73 Bn | ₹46.73 Bn | ₹51.23 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹11.77 Bn | ₹21.34 Bn | ₹44.87 Bn | ₹19.60 Bn | ₹1.13 Bn | ₹1.47 Bn | ₹50.40 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹11.49 | ₹20.84 | ₹43.84 | ₹19.30 | ₹38.14 | ₹44.97 | ₹50.09 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹11.49 | ₹20.84 | ₹43.84 | ₹19.30 | ₹38.14 | ₹44.97 | ₹50.09 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ZYDUSLIFE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).